Endocrine Toxicity

OVERVIEW

GUIDELINES

Endocrinopathies – Adrenal Insufficiency, Hypophysitis, and Thyrotoxicosis1

Endocrinopathies – Hypothyroidism2

Endocrinopathies – Thyroid Toxicity, Hypophysitis3

Hyperthyroidism/Hypothyroidism4

PEMBROLIZUMAB: INCIDENCE

Immune-mediated Adrenal Insufficiency

ONSET & DURATION

Pembrolizumab: imAE Median Times to Onset and Duration in Affected Patients-Endocrinopathies1,2

References:

  1. NCCN (National Comprehensive Cancer Network) V.1.2023. Accessed at: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Last accessed: 1-5-2023
  2. Schneider J, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of clinical oncology. 2023;39(36):4073-126
  3. Haanen , Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2022;33(12):1217-38.
  4. Ahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for immunotherapy of cancer. 2021;9(6).
  5. Egyptian drug authority KEYTRUDA® leaflet approval date: 23/05/2023.

Connect with us on social

MSD Egypt, 67 – El Tesseen St., Address Building, Fifth Settlement, New Cairo.
In case you need any updates or you have an inquiry or need to report on an adverse reaction, you can contact:

+20226145100

dpoc_egypt@merck.com

Veeva Code: EG-KEY-00280

Expiration Date: 10/07/2024